Relan Shilpi, Alarcon Guido, Guffey Danielle, Minard Charles G, Fang Mary E, Timmons Kelly, Sonabend Rona Y, Tosur Mustafa, Redondo Maria J, Posey Jennifer E
Baylor College of Medicine, Texas Children's Hospital, Houston, TX, USA.
Dan L Duncan Institute for Clinical and Translational Research, Baylor College of Medicine, Houston, TX, USA.
J Clin Endocrinol Metab. 2025 Jun 24. doi: 10.1210/clinem/dgaf360.
Current practice guidelines recommend considering a diagnosis of maturity-onset diabetes of the young (MODY) in patients with diabetes with an affected parent but without typical features of type 1 diabetes (T1D) or type 2 diabetes (T2D).
To test if these criteria apply to a real-world cohort of racially/ethnically diverse children with diabetes.
We performed a retrospective case review of electronic medical records (EMR) of youth diagnosed with MODY in a large academic pediatric hospital in Southwestern U.S. Cases were ascertained based on the identification of a molecular diagnosis of MODY.
We studied 50 genetically confirmed cases of MODY: 60% GCK-MODY (MODY2, n=30), 16% HNF1A-MODY (MODY3, n=8), 18% HNF1B-MODY (MODY5, n=9), 4% HNF4A-MODY (MODY1, n=2), and 2% with a dual molecular diagnosis resulting from variants in more than one MODY gene (n=1). Race/ethnicity other than non-Hispanic White, lack of parental diabetes history, obesity/overweight at diagnosis, dyslipidemia and/or hypertension and acanthosis nigricans documented on physical exam were observed, respectively, in 52% (n=26), 24% (n=12), 22.2% (n =11), 30% (n=15), and 12% (n=6) of MODY cases. Furthermore, islet antibody positivity was observed in 8% of the cases GCK-MODY (n=4). The mean hemoglobin A1c at diabetes diagnosis was higher in patients with HNF4A-MODY (7.0%), HNF1A-MODY (6.7%), and HNF1B-MODY (6.7%), than in those with GCK-MODY (6.1%, p=0.005). Four (13.3%) GCK-MODY patients had persistent proteinuria of undetermined cause.
The current guidelines to consider a diagnosis of MODY may not apply to a racially/ethnically diverse U.S. population of children with diabetes.
当前的实践指南建议,对于父母患有糖尿病但无1型糖尿病(T1D)或2型糖尿病(T2D)典型特征的糖尿病患者,应考虑诊断为青年发病的成年型糖尿病(MODY)。
检验这些标准是否适用于种族/民族多样化的糖尿病儿童真实队列。
我们对美国西南部一家大型学术儿科医院诊断为MODY的青少年电子病历(EMR)进行了回顾性病例审查。病例通过确定MODY的分子诊断来确定。
我们研究了50例基因确诊的MODY病例:60%为GCK-MODY(MODY2,n = 30),16%为HNF1A-MODY(MODY3,n = 8),18%为HNF1B-MODY(MODY5,n = 9),4%为HNF4A-MODY(MODY1,n = 2),2%因多个MODY基因变异导致双重分子诊断(n = 1)。在MODY病例中,分别有52%(n = 26)、24%(n = 12)、22.2%(n = 11)、30%(n = 15)和12%(n = 6)观察到非西班牙裔白人以外的种族/民族、缺乏父母糖尿病病史、诊断时肥胖/超重、血脂异常和/或高血压以及体检记录的黑棘皮病。此外,在8%的GCK-MODY病例(n = 4)中观察到胰岛抗体阳性。HNF4A-MODY(7.0%)、HNF1A-MODY(6.7%)和HNF1B-MODY(6.7%)患者在糖尿病诊断时的平均糖化血红蛋白水平高于GCK-MODY患者(6.1%,p = 0.005)。四名(13.3%)GCK-MODY患者出现原因不明的持续性蛋白尿。
当前考虑诊断MODY的指南可能不适用于美国种族/民族多样化的糖尿病儿童人群。